Order results by:
| Issue | Title | |
| Vol 17, No 5 (2025) | Cerebrovascular diseases in the context of type 2 diabetes mellitus: cognitive impairment and associated brain status and metabolic characteristics | Abstract similar documents |
| M. M. Tanashyan, K. V. Antonova, A. A. Panina, O. V. Lagoda, N. E. Spryshkov, A. N. Sergeeva, G. I. Khvastochenko | ||
| "... in patients with DM2: Fazekas III brain damage in 23.2% of patients, Fazekas II in 36.2%, Fazekas II–III ..." | ||
| Vol 13, No 2 (2021) | Depression, anxiety and motivation in arterial hypertension | Abstract similar documents |
| S. K. Mezhmidinova, V. V. Zakharov, N. V. Vakhnina | ||
| "... with MiniMental State Examination, Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery. EBD ..." | ||
| Vol 15, No 1 (2023) | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program | Abstract similar documents |
| E. Y. Solovieva, P. R. Kamchatnov, L. B. Novikova, O. A. Kicherova, N. M. Khasanova | ||
| "... (MoCA). An extension of the standard MoCA testing – MoCA-Memory Index Score (MoCA-MIS; Memory Index, MI ..." | ||
| Vol 14, No 4 (2022) | Effect of statins on oxidative stress and cognitive function in patients with cerebral atherosclerosis: results of a prospective cohort study | Abstract similar documents |
| K. V. Nikulina, O. V. Vorobieva, V. V. Fateeva | ||
| "... of oxidative stress using Fe2+-induced chemiluminescence and cognitive phenotype, using the MoCA test ..." | ||
| Vol 17, No 5 (2025) | Changes in quantitative magnetic resonance imaging susceptibility mapping in Alzheimer's disease | Abstract similar documents |
| M. B. Dolgushin, M. Yu. Martynov, A. V. Dvoryanchikov, A. A. Kuznetsov, A. N. Bogolepova, D. V. Sashin, R. V. Nadelyaev, R. T. Tairova | ||
| "... included 11 patients with AD (five women and six men; mean age 75.3±9.4 years; MoCA score 11.2±3.9) and 12 ..." | ||
| Vol 15, No 1 (2023) | Adherence to treatment in patients with cerebrovascular disease as a multifactorial problem | Abstract similar documents |
| M. M. Tanashyan, K. V. Antonova, O. V. Lagoda, A. A. Kornilova, E. P. Shchukina | ||
| "... Test (MoCA) was 21 points, in patients with very high adherence – 26 points. An increase in the total ..." | ||
| Vol 16, No 6 (2024) | Comparative efficacy of inhaled nitric oxide therapy (Tianox device) in mild cognitive impairment | Abstract similar documents |
| D. A. Grishina, Yu. A. Starchina, E. A. Sokolov, V. A. Parfenov | ||
| "... (p<0.05) improvement in CF was found according the Montreal Cognitive Assessment (MoCA-test), Frontal ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy) | Abstract similar documents |
| V. A. Parfenov | ||
| "... factors, and manifestations, Stages I and II DEP largely corresponds to moderate VCI; Stage III DEP does ..." | ||
| Vol 13, No 1 (2021) | The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’ | Abstract similar documents |
| V. V. Kovalchuk | ||
| "... to Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Multidimensional ..." | ||
| Vol 12, No 5 (2020) | The etiology, manifestations, and therapy of chronic cerebrovascular diseases | Abstract similar documents |
| A. G. Gogoleva, V. V. Zakharov | ||
| "... цереброваскулярных заболеваний (ЦВЗ), обсуждается роль артериальной гипертензии, церебральной амилоидной ангиопатии ..." | ||
| Vol 10, No 1 (2018) | Chronic cerebrovascular diseases: pathogenetic mechanisms, clinical manifestations, and approaches to therapy | Abstract similar documents |
| N. V. Pizova | ||
| "... заболеваний (ЦВЗ) при различных распространенных соматических болезнях, таких как артериальная гипертензия ..." | ||
| Vol 11, No 4 (2019) | Clinical experience with piribedil in chronic cerebrovascular disease with cognitive impairment | Abstract similar documents |
| E. V. Moroz, T. A. Zakharycheva, M. V. Antonyuk | ||
| Vol 4, No 1 (2012) | Current approaches to therapy for chronic forms of cerebrovascular diseases | Abstract similar documents |
| Maksim Alekseyevich Domashenko, M Yu Maksimova, T A Popova, M M Tanashyan | ||
| "... Обсуждаются вопросы клиники и лечения хронических форм цереброваскулярных заболеваний (ЦВЗ ..." | ||
| Vol 3, No 1 (2011) | Clinical experience with Neurox used in patients with cerebrovascular disease | Abstract similar documents |
| N. G. Mayorova, V. A. Pavlov | ||
| "... (нейрокса) в составе комплексной терапии у 32 пациентов с цереброваскулярными заболеваниями - ЦВЗ: 10 ..." | ||
| Vol 10, No 4 (2018) | Chronic cerebrovascular diseases: use of vinpocetine in neurological practice (Round Table proceedings) | Abstract similar documents |
| V. A. Parfenov, S. A. Zhivolupov, V. V. Zakharov, L. A. Belova, O. V. Lagoda, R. G. Esin, N. V. Vakhnina, I. N. Samartsev | ||
| "... цереброваскулярным заболеваниям (ЦВЗ). Отмечено, что хроническая ишемия головного мозга (ХИГМ), или дисциркуляторная ..." | ||
| Vol 16, No 3 (2024) | Impact of COVID-19 on mild vascular cognitive impairment in patients with atrial fibrillation: results of a three-year observational study | Abstract similar documents |
| O. V. Vorob'eva, N. N. Shindryaeva, V. V. Fateeva | ||
| "... months using Montreal Cognitive Assessment (MoCA). The study took place during COVID-19 pandemic, and 25 ..." | ||
| Vol 7, No 1 (2015) | Cognitive impairments in cerebrovascular disease: What is between health and dementia? | Abstract similar documents |
| A. Yu. Emelin | ||
| "... распространенности как острых, так и хронических форм цереброваскулярных заболеваний (ЦВЗ). Среди разнообразных ..." | ||
| Vol 15, No 4 (2023) | The role of trimethylamine-N-oxide in the development of cerebrovascular disease (brief review) | Abstract similar documents |
| M. A. Kutlubaev, A. R. Rakhmatullin, R. F. Kutlubaeva | ||
| "... ТМО в развитии цереброваскулярного заболевания (ЦВЗ). Необходимо продолжить изучение новых соединений ..." | ||
| Vol 7, No 1 (2015) | Clinical experience with L-lysine escinate for acute and chronic cerebral circulatory disorders | Abstract similar documents |
| N. V. Pizova | ||
| "... Цереброваскулярные заболевания (ЦВЗ) являются основными причинами инвалидизации и смертности ..." | ||
| Vol 15, No 5 (2023) | Efficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, A. S. Agafina, N. V. Lyamina, M. M. Gavrik, L. R. Kuchumova, E. R. Barantsevich, V. S. Krasnov, A. A. Ivanova, A. L. Vladykin, K. А. Ishchenko | ||
| Vol 12, No 6 (2020) | Cognitive and emotional impairment in patients with migraine and signs of leukoencephalopathy during preventive therapy | Abstract similar documents |
| K. A. Pozhidaev, V. A. Parfenov | ||
| "... ; the Benton visual retention test, the Munsterberg test; the Montreal Cognitive Assessment (MoCA), the trail ..." | ||
| Vol 12, No 5 (2020) | Cognitive function dynamics in comorbid patients after angioreconstructive interventions | Abstract PDF (Eng) similar documents |
| M. M. Tanashyan, K. V. Antonova, O. V. Lagoda, E. S. Berdnikovitch, R. B. Medvedev, I. I. Titkova, A. V. Naminov, A. V. Annushkin | ||
| "... (ЦВЗ) общеизвестно. Вместе с тем недостаточно освещены вопросы прогноза у коморбидных пациентов, в ..." | ||
| Vol 15, No 2 (2023) | Antioxidant therapy in the complex treatment of patients with ischemic stroke in the acute and recovery period | Abstract similar documents |
| Yu. A. Belova, S. V. Kotov | ||
| "... according to the Montreal Cognitive Scale (MoCA), and an increase in the MoCA score by 2 points or more ..." | ||
| Vol 12, No 4 (2020) | Experience with citicoline in patients with post-stroke cognitive impairment | Abstract similar documents |
| A. N. Bogolepova, S. G. Burd, A. V. Lebedeva, E. A. Kovalenko | ||
| "... Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The presence of anxiety-depressive spectrum ..." | ||
| Vol 14, No 2 (2022) | Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders | Abstract similar documents |
| M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... Assessment (MoCA); 2) Hamilton Anxiety Rating Scale (HAM-A); 3) Subjective assessment of asthenia scale; 4 ..." | ||
| Vol 16, No 1 (2024) | Treatment of cognitive impairment in patients with cerebral infarction in the internal carotid arteries circulation system: results of a multicentre, randomized, double-blind, placebo-controlled clinical trial | Abstract similar documents |
| D. R. Khasanova, A. A. Yakupova, P. R. Kamchatnov, Zh. Yu. Chefranova, E. I. Bogdanov, P. I Pilipenko, N. M. Khasanova | ||
| "... points on the Montreal Cognitive Assessment, MoCA), full consciousness (15 points on the Glasgow Coma ..." | ||
| Vol 15, No 1 (2023) | Management of patients with cognitive impairment | Abstract similar documents |
| V. A. Parfenov | ||
| "... цереброваскулярного заболевания (ЦВЗ). Некоторые нелекарственные и лекарственные методы могут уменьшить проявления КН ..." | ||
| Vol 9, No 3 (2017) | Possibilities of therapy for early manifestations of chronic cerebral ischemia: results of the PROFILE program | Abstract similar documents |
| G. R. Tabeeva, E. Yu. Kalimeeva, N. N. Koberskaya, S. I. Gereeva | ||
| "... ) у пациентов с начальными проявлениями хронического цереброваскулярного заболевания (ЦВЗ) в ..." | ||
| Vol 15, No 6 (2023) | The use of inhaled nitric oxide (Tianox device) in patients with moderate cognitive impairment | Abstract similar documents |
| Yu. A. Starchina, D. A. Grishina, E. A. Sokolov, V. A. Parfenov | ||
| "... азота (аппарат «Тианокс») у пациентов с УКН, вызванными цереброваскулярными (ЦВЗ) и нейродегенеративными ..." | ||
| Vol 14, No 2 (2022) | New potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation. | Abstract similar documents |
| A. K. Minochkin, V. Yu. Lobzin, N. N. Suchentseva, O. S. Popov, S. V. Apalko, S. G. Sherbak | ||
| "... Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA), and etc. Results and discussion ..." | ||
| Vol 4, No 2 (2012) | Evolution of cognitive deficit: mild and moderate cognitive impairments | Abstract similar documents |
| V V Zakharov | ||
| "... neuropsychological tests, such as the Montreal Cognitive Assessment (MoCA) test should be used to diagnose non ..." | ||
| Vol 14, No 1 (2022) | Effect of vitamin D and other indicators of phosphorus-calcium metabolism on cognitive functions and quality of life in patients with Parkinson's disease | Abstract similar documents |
| D. A. Novotnyy, N. G. Zhukova, L. P. Shperling, V. A. Stolyarova, I. A. Zhukova, A. E. Agasheva, S. V. Shtaimets, O. A. Druzhinina, I. V. Shirokikh | ||
| "... functions (CF) according to MoCA. Then, we analyzed the effect of vitamin D levels and other indicators ..." | ||
| Vol 10, No 4 (2018) | Impact of stimulating cognitive-motor training on neuropsychological status and quality of life in patients with Parkinson's disease | Abstract similar documents |
| Yu. N. Bykov, T. B. Bender, Yu. N. Vasiliev, A. N. Kalyagin, Т. М. Maksikova, G. M. Orlova, N. M. Kozlova, O. V. Ryzhkova | ||
| "... Cognitive Assessment (MoCA), the McNair and Kahn memory self-evaluation scale, the Hospital Anxiety ..." | ||
| Vol 12, No 3 (2020) | Cerebral structural and functional changes in diabetes mellitus | Abstract similar documents |
| M. V. Matveeva, Yu. G. Samoilova, N. G. Zhukova, I. V. Tolmachev, E. E. Ermak, O. S. Tonkih | ||
| "... . The Montreal Cognitive Assessment (MoCA test) was used to evaluate CI. Glycemia and its variability ..." | ||
| Vol 12, No 1 (2020) | The efficacy and safety of ethyl methyl hydroxypyridine succinate used as part of sequential therapy in patients with chronic cerebral ischemia | Abstract similar documents |
| V. V. Burdakov, D. V. Krasnykh | ||
| "... Cognitive Assessment (MoCA); the Hamilton Anxiety Rating Scale (HARS); asthenia rating scales ..." | ||
| Vol 11, No 1 (2019) | Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study) | Abstract similar documents |
| I. N. Samartsev, S. A. Zhivolupov, Yu. S. Butakova, M. V. Morozova, I. N. Barsukov | ||
| "... ), the Montreal Cognitive Assessment (MoCA), the 5-point Likert scale, and videonystagmographic tests. Plasma ..." | ||
| Vol 16, No 5 (2024) | Asthenia and vascular cognitive impairment in young patients after stroke | Abstract similar documents |
| L. A. Shchepankevich, K. V. Rerikh, M. S. Ponomareva, A. V. Zatynko, E. V. Taneeva | ||
| "... was assessed by Montreal Cognitive Assessment (MoCA) and asthenia by manifestations of general fatigue ..." | ||
| Vol 13, No 4 (2021) | Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approaches | Abstract similar documents |
| A. N. Bogolepova, N. A. Osinovskaya, E. A. Kovalenko, E. V. Makhnovich | ||
| "... , and emotional disturbances. The evaluation included neurological exam, Montreal Cognitive Assessment Scale (MoCA ..." | ||
| Vol 15, No 1 (2023) | Efficacy of a combination of non-drug therapies in patients with non-dementia vascular cognitive impairment | Abstract similar documents |
| M. S. Novikova, V. V. Zakharov, N. V. Vakhnina | ||
| "... compared to the first visit: Montreal Cognitive Function Assessment Scale (MoCA-test) – from 22.5±2.4 to 23 ..." | ||
| Vol 12, No 1 (2020) | Experience with vortioxetine in the treatment of post-stroke depression | Abstract similar documents |
| I. A. Strelnikova, A. A. Svetkina, Yu. D. Minina, O. V. Androfagina | ||
| "... with the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). For evaluation ..." | ||
| Vol 16, No 2 (2024) | Effects of rehabilitation on functional independence in daily life, exercise tolerance and quality of life in patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| Ya. G. Pekhova, M. Yu. Martynov, I. A. Belayeva, A. S. Ryabov, A. A. Vershinin, A. N. Boiko | ||
| "... functioning (SF). Cognitive functioning was assessed using the Montreal Cognitive Scale (MoCA) and depression ..." | ||
| Vol 10, No 2 (2018) | Pre-stroke cognitive impairment and its impact on medication adherence | Abstract similar documents |
| E. A. Kovalenko, A. N. Bogolepova | ||
| "... of the patients was 64.18±10.24 years. The Montreal Cognitive Assessment (MoCA) was applied to assess cognitive ..." | ||
| Vol 15, No 4 (2023) | Clinical experience with the use of citicoline in mild cognitive impairment of vascular origin | Abstract similar documents |
| L. A. Shchepankevich, I. A. Gribacheva, T. F. Popova, E. V. Taneeva, K. V. Roerich, E. V. Petrova, M. S. Shchepankevich | ||
| "... patients were assessed with a neuropsychological status assessment (MoCA-test). The efficacy of therapy ..." | ||
| Vol 16, No 3 (2024) | Clinical and neurophysiological features of the augmentation phenomenon in restless legs syndrome | Abstract similar documents |
| N. A. Gorbachev, A. V. Obukhova, L. A. Fedeneva, M. G. Poluektov | ||
| "... (RS), Montreal Cognitive Assessment Scale (MoCA), Beck Anxiety Inventory, Beck Depression Inventory ..." | ||
| Vol 14, No 4 (2022) | Cognitive dysfunction in patients with Chiari malformation type 1 and its relationship with the degree of cerebellar tonsil ectopia | Abstract similar documents |
| R. G. Kokurkina, E. G. Mendelevich | ||
| "... State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the Trail Making Test (TMT ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Rehabilitation of patients with progressive forms of multiple sclerosis | Abstract similar documents |
| S. A. Sivertseva, K. S. Anfilofyeva, A. V. Zotova, A. A. Belkin, M. A. Sherman | ||
| "... Assessment (MoCA test), Symbol Digit Modalities Test (SDMT). Results and discussion. Statistically ..." | ||
| Vol 11, No 2 (2019) | Comparative study of pharmacological correction strategies for moderate cognitive impairment in hypertensive patients | Abstract similar documents |
| O. V. Vorobyeva, Zh. M. Sizova, L. M. Bogatyreva | ||
| "... of treatment, the Montreal Cognitive Assessment (MoCa) scores increased from 24.5Ѓ}0.8 to 27.5Ѓ}0.6 (p<0 ..." | ||
| Vol 14, No 3 (2022) | The impact of non-motor disorders on the quality of life of patients with cervical muscular dystonia | Abstract similar documents |
| M. R. Nodel, N. I. Salouhina, V. A. Tolmacheva | ||
| "... ), Montreal Cognitive Assessment Scale (MoCA), Stroop Test (VST), 12 Word Memory Test, Pittsburgh Sleep ..." | ||
| Vol 10, No 3 (2018) | Effect of indapamide/perindopril fixed-dose combination on 24-hour blood pressure and cognitive functions in treatment-naive middle-aged patients with essential arterial hypertension | Abstract similar documents |
| T. M. Ostroumova, V. A. Parfenov, O. D. Ostroumova, E. V. Borisova | ||
| "... functions using the Montreal Cognitive Assessment (MoCA), ten-words test (immediate and delayed word recall ..." | ||
| Vol 16, No 5 (2024) | Clinical features of vascular cognitive impairment | Abstract similar documents |
| O. O. Martynova, N. V. Vakhnina, V. V. Zakharov | ||
| "... function (MoCA test, MMSE); general EF (FAB, EXIT-25); episodic memory (12-word memory test and Benton ..." | ||
| Vol 17, No 1 (2025) | Emotional disturbances in patients in the remote postoperative period after surgical treatment of cerebral aneurysms | Abstract PDF (Eng) similar documents |
| I. M. Shetova I.M, T. A. Shatokhin, V. A. Luk'yanchikov, A. A. Yakovlev, M. A. Piradov, V. V. Krylov | ||
| "... the Barthel Index and the modified Rankin Scale), cognitive functioning (using the MoCA test) and emotional ..." | ||
| Vol 2, No 2 (2010) | Cervicogenic headache: the specific features of complex therapy with Amelotex and CompligamV | Abstract similar documents |
| M. L. Pospelova | ||
| "... redetermination of the levels of von Willebrand factor, factor VIII, antithrombin III, D-dimer, and homocysteine ..." | ||
| Vol 7, No 1 (2015) | Vascular cognitive impairments in chronic kidney disease | Abstract similar documents |
| I. V. Rogova, V. V. Fomin, I. V. Damulin, E. G. Minakova, O. Yu. Selivanova, Yu. A. Petleva | ||
| "... of renal lesion; 20 with Stages III CKD: a GFR of <60–30 ml/min/1.73 m2, and 11 with Stages VI CKD: a GFR ..." | ||
| Vol 12, No 5 (2020) | The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease | Abstract similar documents |
| I. V. Miliukhina | ||
| "... ). The severity of PD motor manifestations was assessed according to the Unified PD Rating Scale (UPDRS) Part III ..." | ||
| Vol 14, No 1 (2022) | COVID-19 associated multiple cranial neuropathies | Abstract similar documents |
| M. Yu. Maksimova, Ya. O. Grusha, E. I. Fettser | ||
| "... cranial nerves involvement (for example, VII, VI, and III) has been described. Patients with COVID-19 ..." | ||
| Vol 12, No 2 (2020) | The role of citicoline in the treatment of dyscirculatory encephalopathy and vascular cognitive impairment | Abstract similar documents |
| V. A. Golovacheva | ||
| "... impairment; stage II DEP to moderate cognitive impairment; stage III DEP to severe cognitive impairment ..." | ||
| Vol 11, No 4 (2019) | Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. N. Spirin, Ya. V. Vlasov, M. N. Zakharova | ||
| "... adequate phases II and III clinical trials. ..." | ||
| Vol 7, No 1S (2015): Special issue "Epilepsy" | A new view on the sociosanitary characteristics of pregnant women with epilepsy | Abstract similar documents |
| N. V. Golovkina, A. T. Egorova, N. A. Shnayder, D. V. Dmitrenko | ||
| "... , unemployed, a smoker, and has Disability Group II or III due to the underlying disease. Conclusion ..." | ||
| Vol 15, No 6 (2023) | Effect of dopaminergic therapy on lacrimation in Parkinson's disease | Abstract similar documents |
| A. A. Pilipovich, O. V. Vorob'eva, S. A. Makarov, A. V. Kuchuk | ||
| "... of dopaminergic therapy in patients with PD. Material and methods: 43 patients with stage II–III PD according ..." | ||
| Vol 11, No 2 (2019) | Susceptibility-weighted MR imaging (SWI) of basal ganglia iron deposition in the early and advanced stages of Parkinson's disease | Abstract similar documents |
| A. G. Trufanov, A. A. Yurin, A. B. Buriak, S. A. Sandalov, M. M. Odinak, I. V. Litvinenko | ||
| "... the values of iron deposition in the basal ganglia in Stages II and III PD and to determine the relationship ..." | ||
| Vol 11, No 4 (2019) | New possibilities for the therapy of secondary progressive multiple sclerosis | Abstract similar documents |
| A. M. Petrov, E. V. Ivashkova, I. D. Stolyarov | ||
| "... in slowing the progression of disability in patients with SPMS in the international phase III (EXPAND ..." | ||
| Vol 5, No 1 (2013) | Dopamine dysregulation syndrome in Parkinson’s disease | Abstract similar documents |
| A V Nikitina, Natalia Vladimirovna Fedorova | ||
| "... men (n = 6). The patients mainly suffered from the mixed form of the disease. Stages III and IV were ..." | ||
| Vol 10, No 3 (2018) | Median nerve decompression in carpal tunnel syndrome: short- and long-term results | Abstract similar documents |
| A. S. Gilveg, V. A. Parfenov, G. Yu. Evzikov | ||
| "... with surgical treatment. Permanent numbness, subjective weakness, thenar muscle atrophy, stage III CTS ..." | ||
| Vol 17, No 3 (2025) | Autonomic cardiovascular dysregulation and other non-motor manifestations of Parkinson’s disease | Abstract similar documents |
| A. A. Pilipovich, O. V. Vorob'eva, S. A. Makarov | ||
| "... stages I–III were examined. The evaluation included: a questionnaire aimed at identifying symptoms ..." | ||
| Vol 8, No 2 (2016) | Psychogenic dystonia of the hand: A clinical case | Abstract similar documents |
| A. I. Baidauletova, O. A. Shavlovskaya | ||
| "... положении кисти) и пальцев (перекрещивание III и IV пальцев), уменьшающие проявления двигательного ..." | ||
| Vol 14, No 6 (2022) | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study | Abstract similar documents |
| Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova | ||
| "... .62 years versus 5.12±3.24 years) and had a more pronounced (III–IV) stage of the disease. These patients ..." | ||
| Vol 10, No 4 (2018) | Immunophenotypic characteristics of brain metastases | Abstract similar documents |
| G. A. Demyashkin, E. A. Shalamova, P. V. Nikitin, S. N. Bogomolov | ||
| "... and an immunohistochemical (IHC) panel including EMA, CK AE1/3, CK7, CK5/6, GFAP, S-100, Vimentin, p63, TTF-1, Uroplakin III ..." | ||
| Vol 12, No 4 (2020) | Trigeminal neuropathy following orthognathic surgery | Abstract PDF (Eng) similar documents |
| M. M. Tanashyan, M. Yu. Maksimova, S. Yu. Ivanov, E. M. Musaeva, P. A. Fedin | ||
| "... showed shortening in the interpeak intervals III–V; those on TEPs demonstrated a decrease in the P1–N1 ..." | ||
| Vol 11, No 2S (2019): Спецвыпуск: боль в спине и конечностях | Carpal tunnel syndrome: issues of diagnosis and treatment | Abstract similar documents |
| A. S. Gilveg, V. A. Parfenov, G. Yu. Evzikov | ||
| "... muscle atrophy, Stage III CTS, and diabetes mellitus are predictors for less pronounced improvement ..." | ||
| 1 - 70 of 83 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
